Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities

Osteoporotic fractures impose substantial morbidity and mortality among older adults. Undertreatment is an ongoing concern; treatment rates declined following reports of adverse effects of guideline-recommended bisphosphonates, but new antiresorptives have since become available. Our goal was to ide...

Full description

Saved in:
Bibliographic Details
Main Authors: Kimberly E Lind (Author), Mikaela L Jorgensen (Author), Leonard C Gray (Author), Andrew Georgiou (Author), Johanna I Westbrook (Author)
Format: Book
Published: SAGE Publishing, 2019-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8374aa18a95e4dc99458ace77ba3ee9d
042 |a dc 
100 1 0 |a Kimberly E Lind  |e author 
700 1 0 |a Mikaela L Jorgensen  |e author 
700 1 0 |a Leonard C Gray  |e author 
700 1 0 |a Andrew Georgiou  |e author 
700 1 0 |a Johanna I Westbrook  |e author 
245 0 0 |a Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities 
260 |b SAGE Publishing,   |c 2019-05-01T00:00:00Z. 
500 |a 1178-6329 
500 |a 10.1177/1178632919852111 
520 |a Osteoporotic fractures impose substantial morbidity and mortality among older adults. Undertreatment is an ongoing concern; treatment rates declined following reports of adverse effects of guideline-recommended bisphosphonates, but new antiresorptives have since become available. Our goal was to identify contemporary trends in osteoporosis treatment guideline adherence in a high fracture-risk population. We conducted a secondary data analysis using electronic health record data of adults aged ⩾65 years from 68 residential aged care facilities in Australia during 2014-2017 (n = 9094). Using medication administration data, we identified antiresorptive (bisphosphonates and denosumab) and vitamin D supplement use among residents with osteoporosis. Regression was used to evaluate temporal trends, and resident and facility characteristics associated with antiresorptive use and vitamin D use. In 2014, 34% of women and 42% of men with osteoporosis used antiresorptives; this decreased 8 percentage points by 2017. Antiresorptive use was higher among those with a history of fracture and lower in the last year of life. Denosumab use increased but did not substitute for the continued decline in bisphosphonate use. Vitamin D was consistently used by more than 60% of residents and was higher among those with fracture history. Greater attention to the treatment of osteoporosis treatment rates among this high fracture-risk population is warranted. 
546 |a EN 
690 |a Medicine (General) 
690 |a R5-920 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Health Services Insights, Vol 12 (2019) 
787 0 |n https://doi.org/10.1177/1178632919852111 
787 0 |n https://doaj.org/toc/1178-6329 
856 4 1 |u https://doaj.org/article/8374aa18a95e4dc99458ace77ba3ee9d  |z Connect to this object online.